Business Description
IDL Biotech AB
NAICS : 621511
SIC : 8071
ISIN : SE0012193340
Share Class Description:
XSAT:IDL: BDescription
IDL Biotech AB develops, produces and markets In Vitro Diagnostic tests for the health care sector. It offers in vitro diagnostic tests within the clinical areas of oncology and bacteriology. The company's trademark products includes TUBEX, TPS, UBC, MonoTotal and TPAcyk.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.62 | |||||
| Equity-to-Asset | 0.61 | |||||
| Debt-to-Equity | 0.27 | |||||
| Debt-to-EBITDA | -0.48 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 5.13 | |||||
| Beneish M-Score | -3.62 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -33.7 | |||||
| 3-Year FCF Growth Rate | -91.3 | |||||
| 3-Year Book Growth Rate | 21 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 6-1 Month Momentum % | 53.03 | |||||
| 12-1 Month Momentum % | 16 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.02 | |||||
| Quick Ratio | 1.41 | |||||
| Days Inventory | 383.83 | |||||
| Days Sales Outstanding | 64.9 | |||||
| Days Payable | 139.05 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -16.2 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 72.85 | |||||
| Operating Margin % | -65.26 | |||||
| Net Margin % | -65.7 | |||||
| FCF Margin % | -52.77 | |||||
| ROE % | -51.13 | |||||
| ROA % | -33.93 | |||||
| ROIC % | -56.42 | |||||
| ROC (Joel Greenblatt) % | -119.77 | |||||
| ROCE % | -43.81 | |||||
| Years of Profitability over Past 10-Year | 4 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 9.26 | |||||
| PB Ratio | 9.63 | |||||
| Price-to-Tangible-Book | 15.16 | |||||
| EV-to-EBIT | -13.93 | |||||
| EV-to-EBITDA | -17.31 | |||||
| EV-to-Revenue | 9.09 | |||||
| Price-to-Median-PS-Value | 3.89 | |||||
| Price-to-Net-Current-Asset-Value | 28.8 | |||||
| Earnings Yield (Greenblatt) % | -7.18 | |||||
| FCF Yield % | -5.65 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
IDL Biotech AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 19.642 | ||
| EPS (TTM) (kr) | -0.202 | ||
| Beta | 0 | ||
| Volatility % | 67.04 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (kr) | 0.184286 | ||
| 20-Day SMA (kr) | 0 | ||
| 12-1 Month Momentum % | 16 | ||
| 52-Week Range (kr) | 1.2 - 3.69 | ||
| Shares Outstanding (Mil) | 63.06 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
IDL Biotech AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
IDL Biotech AB Stock Events
| Event | Date | Price(kr) | ||
|---|---|---|---|---|
| No Event Data | ||||
IDL Biotech AB Frequently Asked Questions
What is IDL Biotech AB(XSAT:IDL)'s stock price today?
The current price of XSAT:IDL is kr2.88. The 52 week high of XSAT:IDL is kr3.69 and 52 week low is kr1.20.
When is next earnings date of IDL Biotech AB(XSAT:IDL)?
The next earnings date of IDL Biotech AB(XSAT:IDL) is .
Does IDL Biotech AB(XSAT:IDL) pay dividends? If so, how much?
IDL Biotech AB(XSAT:IDL) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers